Stephen J. Hoffman, PhD, MD

Dr. Hoffman has served as a director on the Talphera Board of Directors since February 2010. From December 2017 to October 2019, he served as Chief Executive Officer and Director of Aerpio Pharmaceuticals, Inc. Beginning in February 2014, Dr. Hoffman was a Senior Advisor to PDL BioPharma, Inc., and served as a Managing Director at Skyline Ventures, a venture capital firm, from May 2007 to February 2014. From January 2003 to March 2007, he was a general partner at TVM Capital, a venture capital firm. From 1994 to 2012, Dr. Hoffman served as President, Chief Executive Officer, and Director of Allos Therapeutics, a biopharmaceutical company, and served as chairman of the board of directors from 2002 until its acquisition by Spectrum Pharmaceuticals in 2012.

From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology at the University of Colorado. He was the scientific founder of Somatogen Inc., a biotechnology company that was acquired in 1998 by Baxter International, Inc., a global medical products and services company, where he held the position of Vice President of Science and Technology from 1987 until 1990.

Dr. Hoffman currently serves on the board of directors of BYOMass Therapeutics, Inc., and Implicit Bioscience, Ltd. He holds a doctorate in bio-organic chemistry from Northwestern University and a medical degree from the University of Colorado School of Medicine.